Magnetic Hyperthermia in Y79 Retinoblastoma and ARPE-19 Retinal Epithelial Cells: Tumor Selective Apoptotic Activity of Iron Oxide Nanoparticle

Hakan Demirci1, Naziha Slimani1, Mercy Pawar1, Ronald E. Kumon2, Prem Vaishnava*,2, and Cagri G. Besirli*,1

1 Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA
2 Department of Physics, Kettering University, Flint, MI, USA

Correspondence: Hakan Demirci, Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, 1000 Wall St, Ann Arbor, MI 48105, USA. e-mail: hdemirci@umich.edu

Received: 4 October 2018
Accepted: 19 June 2019
Published: 27 September 2019

Keywords: magnetic hyperthermia; nanoparticle; dextran-coated iron oxide nanoparticle; retinoblastoma; retina pigment epithelium

Citation: Demirci H, Slimani N, Pawar M, Kumon RE, Vaishnava P, Besirli CG. Magnetic hyperthermia in Y79 retinoblastoma and ARPE-19 retinal epithelial cells: tumor selective apoptotic activity of iron oxide nanoparticle. Trans Vis Sci Tech. 2019;8(5):18, https://doi.org/10.1167/tvst.8.5.18

Copyright 2019 The Authors

Introduction

Retinoblastoma is one of the most common malignant intraocular tumors in children. In the United States, it is estimated that about 12 children per million under the age of 5 years are affected by this cancer.1 In recent years, significant progress has been made in the treatment of retinoblastoma with the introduction of intra-arterial and intravitreal chemotherapy, and as a result, the survival rate reached above 90% in developed countries.2,3 A recent literature review showed that the globe salvage rate is 90% to 100% for groups A to C eyes, more than 70% for group D eyes, and 51% for group E eyes following the intra-arterial chemotherapy. The primary reason for treatment failure in groups D and E was the presence of intravitreous seeds. Intra-arterial chemotherapy requires an experienced team and advanced equipment, which are limited to few centers.4,5 With the recent development of safe injection techniques,
intravitreal injections of the chemotherapeutic agents melphalan and topotecan are being used more commonly. However, intravitreal chemotherapy has the potential to cause ocular toxicity. Therefore, there is an unmet need for new retinoblastoma treatment modalities with a better safety and efficacy profile.

Nanoparticles of various materials can enhance intraocular drug delivery and retention and may have the potential to improve retinoblastoma treatment. Most systems used for drug delivery applications are colloidal suspensions consisting of nanoparticles with a diameter ranging from 10 to 1000 nm, in which the therapeutic agent can be encapsulated or conjugated on the surface of the nanoparticles. Mitra et al. demonstrated that etoposide-loaded poly(lactide-co-glycolide) nanoparticles show 100 times greater antiproliferative and apoptotic gene activity in Y79 retinoblastoma cells compared to native etoposide, indicating the potential of a nanoparticle platform as novel chemotherapy delivery system for retinoblastoma. Similarly, Ahmed et al. reported that carboplatin-loaded protein nanoparticles had greater intracellular uptake and sustained retention, increasing the antiproliferative activity on retinoblastoma cells compared to their soluble counterpart. Qu et al. studied the efficacy of topotecan-loaded mesoporous silica nanoparticles that were surface conjugated with folic acid for the treatment of retinoblastoma. These nanoparticles showed a remarkable uptake in cells compared to the nontargeted nanoparticles, and higher cytotoxicity was observed on retinoblastoma cells. Chitosan nanoparticles, which are biocompatible, relatively nontoxic, and biodegradable in nature, have been used by some researchers due to their improved mucoadhesiveness and ability to cross the epithelial junction. Manasi Das et al. encapsulated anticancer drug nutlin-3a and chemosensitizer curcumin in poly(lactide-co-glycolic acid) nanoparticles, which were surface functionalized with folate to enhance the therapeutic potential and prevent multidrug resistance. Beside poly(lactide-co-glycolic acid) nanoparticles, lipid nanoparticles have been used to codeliver miR-181a and melphalan to retinoblastoma cell lines to decrease the expression of the antiapoptotic gene BCL2 while increasing the expression of proapoptotic gene BAX, thus making the cells more sensitive to melphalan treatment.

Magnetic nanoparticles have recently emerged as a potential modality for the diagnosis and the treatment of cancer. Super paramagnetic nanoparticles of iron oxide have proven particularly beneficial for potential cancer treatment. These materials are also called multifunctional ferrofluids, which are highly stable in aqueous solutions and have been tested for the delivery of hydrophilic and hydrophobic drugs. A ferrofluid that contains super paramagnetic iron oxide nanoparticles can be functionated with many entities, such as an imaging agent and a drug to treat cancer in one unit. This multifunctional unit possesses a unique ability to generate heat when exposed to an alternating magnetic field. Such an ability has a potential application of not only delivering heat to kill cancer cells but also delivering a payload of drug to the tumor, increasing the efficacy of the treatment.

Heat, or hyperthermia, as therapeutic tool has been used for the management of cancer for many years. Previous studies have shown that tumor cells are more sensitive to heat than normal cells. Sustained temperatures above 43°C sensitize tumor cells to respond favorably to radiotherapy or chemotherapy and produce a direct cytotoxic effect. Over the years, the methods of heat application have improved from water baths to noncontact heat-delivery techniques, including radiofrequency, microwaves, and focused ultrasound waves. Recently, magnetic nanoparticles have been used as nanotheraters in the delivery of heat to targeted tumor cells without damaging normal tissue. This phenomenon is commonly known as magnetic hyperthermia. Magnetic nanoparticles typically have a diameter of 2 to 100 nm and can be coated with a biocompatible substance to prevent agglomeration. In magnetic hyperthermia, the application of an alternating magnetic field to the magnetic nanoparticles leads to the coupling of magnetic motions of the nanoparticles with the oscillating field and conversion of the absorbed energy into heat within the targeted tumor tissue. Three distinct mechanisms are involved in heat generation by nanoparticles: Neel relaxation (release of energy by the rotation of the magnetic moment of the nanoparticles), Brownian relaxation (release of the energy by physical rotation of the nanoparticles), and hysteresis loses (when the magnetism of nanoparticles does not follow the magnetism of the applied field).

Hyperthermia was previously used in combination with external beam radiotherapy in the management of uveal melanoma and retinoblastoma. In this paradigm, local heat is generated via ultrasound and microwave probes. Finger utilized a dish-shaped microwave antenna that was placed over the sclera under the tumor at the time of plaque radiotherapy. This antenna delivered heat at a minimum of 42°C for 45 minutes. Hyperthermia in combination with plaque radiotherapy (thermoradiotherapy) reduced...
the tumor apex dose from 100 Gy to a mean of 53 Gy and provided a local control rate of 97% at a mean follow-up of 45 months. In a murine transgenic retinoblastoma model, Murray et al.\textsuperscript{21} tested two ferromagnetic hyperthermia needles placed into the medial and lateral canthi abutting the globe. After applying heat for 20 minutes at 48°C, retinoblastoma was cured in 30% of eyes. When the heat increased to 54°C, the cure rate improved to 100%. Additionally, external beam radiation dose for tumor control in 50% of eyes decreased from 27.6 Gy to 3.3 Gy when combined with magnetic hyperthermia.

Nanoparticles activated by magnetic hyperthermia can produce reactive oxidative species that lead to DNA and mitochondrial damage and protein oxidation.\textsuperscript{22–28} In addition, the activation of the phosphatidylinositol 3-kinase/Akt/Bad pathway by magnetic hyperthermia potentiates the intrinsic proapoptotic factors cytochrome c, caspase 9, and caspase 3, causing apoptotic death.\textsuperscript{22–25} Exposure to a mild heat shock can activate extrinsic apoptotic signaling via FAS signaling in cancer cell lines, including Jurkat and HeLa cells.\textsuperscript{25} Besides the FAS death receptor, magnetic nanoparticles have been shown to induce cell death in human glioma cells via increased tumor necrosis factor alpha (TNF-\textalpha) expression.\textsuperscript{28}

Magnetic nanoparticles as nanoheaters that can deliver targeted heat to tumor tissue have not been previously evaluated in the management of retinoblastoma. With the unique superficial location of the eye and the advancement of safe intravitreal injection techniques, magnetic nanoparticles can easily be used for drug delivery and enhance the effect of current chemotherapeutics. In this study, we assessed the apoptotic effect of dextran-coated iron oxide nanoparticles (DCIONs) activated by a magnetic field on a Y79 retinoblastoma cell line. We evaluated the time course of cell death and the signaling pathways activated during magnetic hyperthermia of Y79 cells. We compared Y79 cell line responses to those seen in ARPE-19 cell line, an in vitro model of retinal pigment epithelium (RPE) cells, as a proxy for one of the retinal cell types that might be adversely affected by this treatment when delivered intravitreally.

**Methods**

**Cell Culture**

The Y79 retinoblastoma cell line was maintained as a suspension culture in RPMI 1640 media (catalog number 30-2001; Invitrogen, Waltham, MA) with 2 mM L-glutamine, 20% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 100 \mu g/ml streptomycin. The ARPE-19 retinal pigment epithelium cell line was cultured in 1:1 DMEM:F12 media (catalog number 30-2006; Invitrogen) containing 2.5 mM L-glutamine, 15 mM HEPES, 10% FBS, 100 U/ml penicillin, and 100 \mu g/ml streptomycin. Both cell lines were plated on 75-cm\(^2\) flasks (catalog number 07-202-000; Fisher Scientific, Ann Arbor, MI) and maintained at 37°C in a humidified atmosphere of 5% CO\(_2\) and 95% air until they reached 90% confluency.

**Magnetic Hyperthermia**

Iron oxide nanoparticles were synthesized using a standard coprecipitation technique in which an aqueous solution of FeCl\(_3\)-6H\(_2\)O and FeCl\(_2\)-4H\(_2\)O were mixed in a 2:1 molar ratio and Fe\(_3\)O\(_4\) nanoparticles were precipitated by the drop-wise addition of 1M NH\(_4\)OH. During precipitation, N\(_2\) gas was bubbled through the solution to protect against oxidation of the Fe\(^{2+}\) ions into Fe\(^{3+}\) ions. The precipitate was separated from the solution by a strong magnet, washed with deionized water and resuspended in a metastable 0.5 M NaOH solution. In order to suspend the precipitated nanoparticles in a carrier solution (deionized water), they were coated in dextran by the drop-by-drop addition of the metastable solution of Fe\(_3\)O\(_4\) to a solution of 15 to 20 kDa dextran (MP Biomedicals, Santa Ana, CA) in 0.5 M NaOH while simultaneously probe sonicating.

Y79 retinoblastoma and ARPE-19 cells were cultured in cryogenic tubes (catalog number 03-337-7D; Fisher Scientific) at a density of 100,000 cells/ml. They were incubated for 24 hours prior to treatment. DCION stock was diluted with the respective culture media to give a dose of 0.25, 0.5, 0.75, or 1 mg/ml. After removing the media, cells were treated for 2 hours to allow receptor-mediated endocytosis (clathrin- and caveolae-mediated endocytosis) in the dose-dependent concentration of nanoparticles, as shown in multiple previous studies.\textsuperscript{29,30} After 2 hours of incubation, media with nanoparticles were removed and fresh media were added. Cells were then treated using a magnetic field with the frequency and intensity values of 250 kHz and 4 kA/m. After reaching a temperature varying between 42 and 46°C, the electromagnetic gradient was kept constant for 30 minutes. Temperature was measured using a fiber optic thermometer (Optocon AG, Dresden, Germany). Controls were untreated Y79 and ARPE-19 cells and those incubated with respective...
concentrations of nanoparticles without magnetic hyperthermia.

**Cell Viability and Caspase Activity Assays**

Hyperthermia-induced apoptosis was assessed at 4, 24, and 72 hours after treatment for both Y79 and ARPE-19 cells. The numbers of viable cells were measured based on quantitation of adenosine triphosphate by using the CellTiter-Glo Luminescent Cell Viability Assay kit (catalog number G7571; Promega, Madison, WI) following the manufacturer’s recommendations. Caspase 8 or 3/7 activity of Y79 cells at the nanoparticle concentration of 1 mg/ml was measured according to manufacturer’s instructions after 48 hours of treatment by using the Caspase-Glo 8 or 3/7 Assay kit (Promega). Luminescence was measured using a Veritas Microplate luminometer (Turner Biosystems, Sunnyvale, CA).

**Transmission Electron Microscopy (TEM) Imaging of DCION Uptake**

TEM was performed to elucidate the cellular uptake and distribution of nanoparticles. Y79 and ARPE-19 cells were cultured in Corning 100-mm plates (catalog number 430167; Fisher Scientific) for 24 hours, after which they were incubated with 1 mg/ml of nanoparticles for 2 hours. After treatment, cells were collected and fixed in 2.5% glutaraldehyde and subsequently postfixed using 1% osmium tetroxide for 3 hours, and then pelleted, dehydrated, infiltrated, and embedded. Finally, ultrathin sections were cut and stained with uranyl acetate. TEM images were taken using a Hitachi HT7700 transmission electron microscope (Tokyo, Japan).

**PCR Assay for Apoptosis Gene Profiling**

Y79 retinoblastoma cells were treated with 1 mg/ml of DCION followed by the induction of a magnetic field to create hyperthermia. The cells were further incubated for 24 hours after magnetic induction. Total RNA was extracted using the RNeasy mini kit (catalog number 74104; Qiagen, Germantown, MD). A total of 25 ng of complementary DNA (cDNA) was then synthesized and pre-amplified using the RT2 PreAMP cDNA Synthesis kit (catalog number 330451; Qiagen) following the manufacturer’s instructions. A solution of 25 μl made of the amplified cDNA diluted with nuclease-free water and RT2 SYBR Green qPCR Mastermix (catalog number 330502; Qiagen) was added to each well of the RT2 Profiler PCR Array Human Apoptosis (catalog number PAHS-012Z; Qiagen) plate. Real-time PCR was performed on a CFX96 PCR system (Bio-Rad Laboratories, Hercules, CA) by using SYBR green detection. The thermocycler parameters consisted of an initial denaturation at 95°C for 10 minutes followed by 39 cycles at 95°C for 15 seconds and annealing at 60°C for 1 minute. The dissociation curve was at 95°C for 1 minute, 55°C for 30 seconds, and 95°C for 30 seconds. All quality-control requirements stated by the manufacturer were fulfilled in the PCR runs (including genomic DNA control, cDNA synthesis control, and positive PCR controls). Relative changes in gene expression were calculated using the delta delta cycle threshold (ΔΔCt) method using SA Bioscience’s PCR Array Data Analysis Web Portal. Gene set enhancement analysis was performed by using web tools, including www.reactome.org and toppgene.cchmc.org. The pathways found to be statistically significant were reported.

**Data Analysis**

Data were analyzed using one-way analysis of variance followed by Tukey’s post hoc test. A value of $P < 0.05$ was considered significant. Prism 7.0 (GraphPad Software, San Diego, CA) was used for all statistical analyses. Results are expressed as mean ± standard error of the mean.

**Results**

We first tested the viability of Y79 retinoblastoma and ARPE-19 RPE cell lines by using different DCION concentrations at 4, 24, and 72 hours following magnetic hyperthermia treatment (Fig. 1). A time- and concentration-dependent cell death was observed in Y79 cells after the application of alternating electromagnetic field. At 4 hours following magnetic hyperthermia, cell death for Y79 cells was 1%, 8%, 17%, and 17% for 0.25, 0.5, 0.75, and 1 mg/ml of DCION concentration, respectively. At 24 hours, cell death in Y79 cells was 47%, 59%, 70%, and 75%, and at 72 hours, cell death was 16%, 45%, 50%, and 56% at DCION concentrations of 0.25, 0.5, 0.75, and 1 mg/ml, respectively. More than half of cells were dead when exposed to 0.75 and 1 mg/ml of DCION concentrations after 24 and 72 hours. In contrast, ARPE-19 cells remained viable up to 88% at 0.25, 0.5, and 0.75 mg/ml of DCION concentrations following magnetic hyperthermia after 24 and 72 hours. There was minimal cytotoxicity of iron oxide nanoparticles to Y79 or ARPE-19 cells for all
Figure 1. ARPE-19 and Y79 retinoblastoma cells were treated with iron oxide nanoparticles, and viability was measured with or without magnetic hyperthermia at 4 (A), 24 (B), and 72 (C) hours. $n = 3$, mean ± SEM, *$P < 0.05$, **$P < 0.005$, ***$P < 0.0005$, ****$P < 0.0001$ for each time point, Tukey test, $N = 3$. 
We evaluated the expression of genes involved in cell death pathways 24 hours after magnetic hyperthermia in Y79 retinoblastoma cells (Fig. 2). Gene set enhancement analysis confirmed the activation of several genes involved in cell death mediated by death receptor signaling, including FAS and TNF-α pathways. *FASLG, TNF, TNFRSF9,* and *TNFRSF1A,* genes involved in FAS and TNF pathways, were expressed at significantly higher levels in Y79 retinoblastoma cells treated with magnetic hyperthermia compared to untreated cells (Table 1). We also measured the effect of DCION exposure alone on gene expression by comparing Y79 retinoblastoma cells treated with or without magnetic hyperthermia. Again, we found that the levels of *FASLG, TNF, TNFRSF9,* and *TNFRSF1A* were significantly elevated after magnetic hyperthermia in Y79 cells when compared to cells exposed to DCION alone (Table 2). Our data demonstrate a global increase in cell death gene expression after magnetic hyperthermia in retinoblastoma cells. This activation leads to a major shift in apoptotic signaling pathways and leads to increased cell death, consistent with the loss of cell viability seen specifically in Y79 cells exposed to DCION-mediated hyperthermia (Fig. 1). Tables 1 and 2 include the top 25 genes seen in our expression profiling experiments. The full list of genes that respond to magnetic hyperthermia after DCION treatment is presented in supplemental Tables 1 and 2.

To confirm the activation of apoptosis, we evaluated caspase 8 and 3/7 activities at 48 hours after magnetic hyperthermia. Caspase 3/7 activity levels were significantly elevated in Y79 cells treated with the magnetic hyperthermia compared to control cells or cells treated with magnetic nanoparticles alone (Fig. 3). In contrast, caspase 8 activity did not increase in Y79 cells after magnetic hyperthermia (Fig. 3). This suggests that the intrinsic apoptotic pathway mediated by mitochondria is the primary cell death mechanism in Y79 cells following hyperthermic insult induced by magnetic nanoparticles.

We next evaluated the localization of DCIONs in Y79 and ARPE-19 cells using TEM. Our data show that nanoparticles were engulfed by both Y79 and ARPE-19 cells (Fig. 4). In ARPE-19 cells, DCIONs were located in lysosomes and endosomes in the
cytoplasm, whereas nanoparticles were distributed throughout cellular structures in Y79 cells.

**Discussion**

Previous studies have shown that 43°C is a critical temperature for the survival of normal and cancer cells. A review of the literature by Leith et al. demonstrated that cell survival decreases exponentially as a function of exposure time at temperatures above 41°C in multiple cancer cell lines, including HeLa, L1210 leukemia, EMT6 mouse mammary sarcoma, and malignant liver cells. Additionally, at the temperatures 43°C or above, cell death increased by a factor of 2 for every 1°C increase in temperature. When the effects of hyperthermia and thermal tolerance were evaluated in the normal human fibroblast cell lines, Rassphorst and Azzam observed that fibroblasts developed thermal tolerance.

| Gene Description | Fold Change |
|-------------------|-------------|
| FASLG FAS ligand | 1133.0533   |
| TNF Tumor necrosis factor | 665.9792   |
| IL10 Interleukin 10 | 646.273    |
| BAG3 BCL2 associated athanogene 3 | 583.8012   |
| CASP14 Caspase 14 | 317.2186   |
| TNFRSF9 TNF receptor superfamily member 9 | 269.2246   |
| PYCARD PYD and CARD domain containing 3 | 265.5181   |
| LTBR Lymphotoxin beta receptor containing 3 | 258.2575   |
| BCL2A1 BCL2 related protein A1 | 140.0049   |
| LTA Lymphotoxin alpha | 130.0269   |
| BIRC3 Baculoviral IAP repeat containing 3 | 112.9338   |

**Table 1.** Top 25 Genes Upregulated 24 Hours After Magnetic Hyperthermia in Y-79 Retinoblastoma Cells Treated With 1 mg/ml of DCIONs Compared to Untreated Cells

| Gene Description | Fold Change |
|-------------------|-------------|
| TNF Tumor necrosis factor | 964.3592   |
| FASLG FAS ligand | 800.8011   |
| BAG3 BCL2 associated athanogene 3 | 632.7203   |
| IL10 Interleukin 10 | 543.3515   |
| CASP14 Caspase 14 | 369.8034   |
| PYCARD PYD and CARD domain containing 9 | 157.6189   |
| TNFRSF9 TNF receptor superfamily member 9 | 129.4063   |

**Table 2.** Top 25 Genes Upregulated 24 Hours After Magnetic Hyperthermia in Y-79 Retinoblastoma Cells Treated With 1 mg/ml of DCIONs Compared to Y-79 Retinoblastoma Cells Exposed to DCIONs Without Magnetic Field Application

| Gene Description | Fold Change |
|-------------------|-------------|
| CD40LG CD40 ligand | 76.4886    |
| CFLAR CASP8 and FADD like apoptosis regulator | 70.8628    |
| CD70 CD70 molecule | 52.6855    |
| CD40 CD40 molecule | 47.9237    |
| CD94 CD94 molecule | 44.0505    |
| BCL2A1 BCL2 related protein A1 | 38.0373    |
| LTBR Lymphotoxin beta receptor | 37.1683    |
| LTBR Lymphotoxin beta receptor | 37.5315    |
| BIRC3 Baculoviral IAP repeat containing 3 | 37.947     |
| CD40LG CD40 ligand | 37.6304    |
| RIK2 Receptor interacting serine/threonine kinase 2 | 37.947     |
| FASLG FAS ligand | 45.187     |
| CD40 CD40 molecule | 42.9574    |
| BCL2A1 BCL2 related protein A1 | 35.5315    |
| TNFSF8 TNF superfamily member 8 | 34.6293    |
| CASP10 Caspase 10 | 34.1119    |
| CD27 CD27 molecule | 33.7515    |
| HRK Harakiri, BCL2 interacting protein | 26.8848    |
| TNFSF10A TNF receptor superfamily member 10a | 21.4137   |
without heat damage. Less than 10% cell death was recorded after 6 to 8 hours of intracellular heating at temperatures less than or equal to 43°C. Between the temperatures of 43 and 44°C, thermal tolerance developed after 2 hours of heating and lasted up to 6 hours. All these experiments were performed with water baths or microwave probes. It is postulated that cancer tissues are relatively hypoxic and acidic secondary to inefficient vascular channels. When exposed to thermal insult, this vascular insufficiency leads to impaired cooling in tumor tissue compared to normal tissue, increasing the sensitivity of cancer to thermal injury. The exact molecular mechanisms of how thermal injury selectively kills tumor cells are largely unknown.

Nanotechnology provides a novel tool for magnetic hyperthermia. Since the first studies by Gordon et al., iron oxide-based nanoparticles with superior magnetic and functionalized surface properties have been used for magnetic hyperthermia in targeted cancer treatment. Ito and Kobayashi evaluated the efficacy of magnetic hyperthermia by using dextran-coated magnetic nanoparticles in animals with various tumors, including B16 mouse melanoma, MM46 mouse mammary carcinoma, PC3, and LNCaP human prostate cancer in athymic mice, spontaneously occurring primary melanoma in transgenic mice, T-9 rat glioma, rat prostate cancer PLS10, Os515 hamster osteosarcoma, VX-7 squamous cell carcinomas in rabbit tongue, and human breast cancer BT-474 (HER2-positive) in nude mice. Direct injection of nanoparticles into the solid tumor followed by magnetic hyperthermia application led to complete tumor regression in 96% of animals. In a clinical trial, Maier-Hauff et al. performed intratumoral injection of iron-oxide nanoparticles in 59 patients with recurrent glioblastoma multiforme.

Magnetic hyperthermia was coupled with a reduced dose of fractionated stereotactic radiotherapy (a median dose of 30 Gy). The median overall survival of patients was 13.4 months, which was considerably longer than the typical median survival of 6 months in patients undergoing conventional radiotherapy. In this paper, we present the first evaluation of magnetic hyperthermia using dextran-coated iron nanoparticles in a retinoblastoma cell line. At 24 hours, one session of magnetic hyperthermia induced 46% to 73% of death in Y79 retinoblastoma cells, suggesting that apoptosis started less than 24 hours after magnetic induction (Fig. 1). Effective cell death was observed with 0.75 and 1 mg/ml of nanoparticle concentration at 24 and 72 hours after magnetic hyperthermia. We observed maximum tumor cytotoxicity at 24 hours. Decreased cell death at 72 hours may indicate that surviving tumor cells continue to proliferate, selecting for resistant cell types. There was minimal cytotoxicity in ARPE-19 cells after 24 and 72 hours of magnetic hyperthermia at all nanoparticle concentrations, demonstrating that magnetic hyperthermia selectively induces cell death in tumor cells in a dose- and time-dependent manner. Our data demonstrate that optimal nanoparticle concentration for tumor cytotoxicity, while having a minimal cytotoxic effect on nontumor cells, was 0.75 mg/ml. However, we acknowledge that there are inherent caveats of studying cytotoxic effects of magnetic hyperthermia in vitro cell culture systems. The differences in cell culture media (10% FBS for ARPE-19 vs. 20% for Y79 cells) and morphologic changes that occur in ARPE-19 cells upon moving from adherent cultures to suspensions in cryotubes may influence the uptake of nanoparticles, which might affect cytotoxicity.

We observed that dextran-coated nanoparticles are...
engulfed in the cytoplasm, lysosomes, and endosomes of the ARPE-19 and Y79 cells. Overgaards\textsuperscript{33} evaluated the ultrastructural changes in mouse mammary carcinoma after hyperthermia. The authors first observed a decrease in cell size with an increase in the number and activity of cytoplasmic lysosomes and disaggregated polyribosomes in the first 6 hours. This was followed by cell shrinkage and reduction in the number of mitochondria within 6 to 24 hours and total disarrangement of cytoplasmic components in 24 hours. Magnetic nanoparticles induced ruffling of the cell surface, which resulted from internalization
via micropinocytosis, forming endosomes. With magnetic hyperthermia, nanoparticles leaked into the cytoplasm and produced reactive oxidative species, which led to DNA and mitochondrial damage and protein oxidation. Fang et al. proposed that magnetic nanoparticles increase the activation of the phosphatidylinositol 3-kinase/Akt/Bad pathway in LOVO cells, leading to the expression of cytochrome c, caspase 9, and caspase 3 proteins. Using TEM, we observed magnetic nanoparticles that were internalized into Y79 retinoblastoma cells. Forty-eight hours after the application of magnetic hyperthermia, caspase 3/7 activity increased selectively in tumor cells, indicating the activation of the mitochondrial cell death pathway. We also observed significant changes in the expression of apoptotic genes, including those involved in FAS and TNF-α signaling. Our gene expression data demonstrated that many signaling pathways involved in cell death were significantly elevated in tumor cells specifically after magnetic hyperthermia. This global change in apoptotic and antiapoptotic gene expression suggests that internalization of nanoparticles and magnetic hyperthermia lead to catastrophic cell damage and kill Y79 cells via both extrinsic and intrinsic apoptotic pathways.

Death receptors, such as the FAS and TNF receptors (FASR, and TNF-R1), are membrane proteins capable of inducing apoptosis and belong to the TNF-R superfamily. Following magnetic hyperthermia, gene expression profiling showed that genes in FAS and TNF-α signaling pathways were highly activated in Y79 retinoblastoma cells, reaching several hundred folds for some genes, including FAS ligand and TNF. Tran et al. showed that exposure to mild heat shock (30 minutes at 42°C) rapidly activated FAS-mediated apoptosis in cancer lines, including Jurkat and HeLa cells. FAS activates caspase-3 not only by inducing the cleavage of the caspase zymogen to its active subunits but also by stimulating the denitrosylation of its active-site thiol. In nude mice carrying human glioma cells, Ito et al. showed that hyperthermia using magnetic nanoparticles induced cell death throughout the tumor area and increased TNF-α gene expression by 3-fold. Our results indicate that FAS and TNF-α pathways are the primary drivers of apoptosis after magnetic hyperthermia treatment in Y79 cells.

Our data demonstrated that DCION treatment had a minimal cytotoxic effect on Y79 or ARPE-19 cells in the absence of magnetic hyperthermia. We found that magnetic hyperthermia via iron nanoparticles was selectively cytotoxic to Y79 retinoblastoma cells, providing evidence for developing magnetic hyperthermia as a potential treatment for retinoblastoma. In addition, we did not detect any caspase activation with iron nanoparticles in the absence of magnetic treatment, demonstrating that hyperthermia is the primary mechanism of tumor toxicity in our model.

Dextran-coated nanoparticles and magnetic hyperthermia might have clinical applications for intraocular tumors. Because intraocular injection is a commonly-used procedure for many retinal diseases, dextran-coated nanoparticles can be easily delivered intravitreally by using existing techniques. Nanoparticle-mediated magnetic hyperthermia can be used as an adjuvant therapy to enhance the outcome of chemotherapy or radiotherapy for eliminating intraocular tumors. However, the penetration of intravitreally delivered dextran-coated nanoparticles into the retinal tissue and the choroid and potential ocular toxicity are unknown. Further studies, including those involving animal models of intraocular tumors, are needed to answer these questions. Modifying nanoparticles with fluorescent labels and staining retinoblastoma tissue with various organelle-specific stains in animal models will also be needed to determine the exact subcellular localization of nanoparticles in vivo applications.

In summary, similar to other cancer cells, Y79 retinoblastoma cells are exquisitely sensitive to thermal damage. We demonstrate that magnetic hyperthermia using dextran-coated iron nanoparticles selectively kills retinoblastoma cells in a dose- and time-dependent manner in vitro, while sparing non-tumor cells. Magnetic hyperthermia induces apoptotic cell death in Y79 cells primarily via the intrinsic pathway activated by FAS and TNF-α signaling. With the recent advent of intravitreal chemotherapeutic injections in the management of retinoblastoma, magnetic hyperthermia with dextran-coated iron nanoparticles may be a promising therapeutic option.

Acknowledgments

Supported by Richard N. and Marilyn K. Witham Professorships (HD).

Disclosure: H. Demirci, Castle Bioscience (C), Immunocore (C); N. Slimani, None; M. Pawar, None; R.E. Kumon, None; P. Vaishnava, None; C.G. Besirli, None

*PV and CGB contributed equally to this article.
References

1. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA. Br J Ophthalmol. 2009;93:21–23.

2. Qu W, Meng B, Yu Y, Wang S. Flic acid conjugated mesoporous silica nanoparticles for enhanced therapeutic efficacy of topotecan in retina cancers. Int J of Nanomedicine. 2018;18:4379–4389.

3. Demirci H, Shields CL, Meadows AR, Shields JA. Long term visual outcome following chemotherapy for retinoblastoma. Arch Ophthalmol. 2005;123:1525–1530.

4. Shields CL, Shield JA. Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey. Clin Exp Ophthalmol. 2010;38:638–643.

5. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203–212.

6. Nishimura S, Sato T, Ueda H, Ueda K. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol. 2001;19:4182–4183.

7. Bhavsar D, Subramanian K, Sethuraman S, Krishnan UM. Management of retinoblastoma: opportunities and challenges. Drug Deliv. 2016;23:2488–2496.

8. Mitra M, Misra R, Harilal A, Sahoo SK, Krishnaumar S. Toxicogenomics of nanoparticle delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy. Cancer Nanotechnol. 2011;2:21–36.

9. Ahmed F, Ali MJ, Kondapi AK. Carboplatin loaded protein nanoparticles exhibit improved anti-proliferative activity in retinoblastoma cells. Int J Biol Macromol. 2014;70:572–582.

10. Khare A, Grover K, Pawar P, Singh I. Mucoadhesive polymers for enhancing retention in ocular drug delivery: a critical review. Rev Adhes Adhes. 2014;2:467.

11. Das M, Sahoo SK. Folate decorated dual drug loaded nanoparticles: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multirug resistance. PLoS One. 2012;7:e32920.

12. Tabatabaei SN, Derbali RM, Yang C, et al. Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma. J Control Release. 2019;298:177–185.

13. Paliwakadana-Arachchige M, Naik VM, Vaishnava PP, Jena B, Naik P. Gd-doped superparamagnetic magnetite nanoparticles for potential cancer theragnostics. In: Seehra MS, ed. Nanostructured Materials - Fabrication to Applications. London, UK: Intech Open; 2017: 79–109. https://doi.org/10.5772/intechopen.68219.

14. Tabatabaei SN, Tabatabaei MS, Giroudard H, Martel S. Hyperthermia of magnetic nanoparticles allows passage of sodium fluorescein and Evans blue dye across the blood-retinal barrier. Int J Hyperthermia. 2016;32:657–665.

15. Prasad NK, Rathinasamy K, Panda D, Bahadur D. Mechanism of cell death induced by magnetic hyperthermia with nanoparticles of γ-MnxFe2–xO3 synthesized by a single step process. J Mater Chem. 2007;17:5042–5051.

16. Abe M, Hiraoka M, Takahashi M, et al. Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (Thermotron RF-8) in combination with radiation for Cancer-Therapy. Cancer. 1986;58:1589–1595.

17. Kobayashi T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol J. 2011;6:1342–1347.

18. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10:787–800.

19. Riedel KG. Hyperthermic therapy procedures for supplementing radiotherapy of malignant intraocular tumors. Klin Monbl Augenheilk. 1988;193:131–137.

20. Finger PT. Microwave theromradiotherapy for intraocular melanoma. Am J Clin Oncol. 1996;19:281–289.

21. Murray TG, O’Brien JM, Steeves RA, et al. Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol. 1996;114:1376–1381.

22. Leith JT, Miller RC, Gerner EW, Boone ML. Hyperthermic potentiation. Biological aspects and applications to radiation therapy. Cancer. 1977;39:766–779.

23. Gerweck LE, Gillette EL, Dewey WC. Effect of heat and radiation on synchronous Chinese hamster cells: killing and repair. Radiat Res. 1975;64:611–623.

24. Giovanella BC, Lohman WA, Heidelberger C. Effects of elevated temperatures and drugs on the viability of L1210 leukemia cells. Cancer Res. 1970;30:1623–1631.

25. Raaphorst GP, Azzam EI. Hyperthermia and thermal tolerance in normal and ataxia telangiectasia human cell strains. Cancer Res. 1983;43:2618–2621.
26. Gordon RT, Hines JR, Gordon D. Intracellular hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alterations. *Med Hypotheses*. 1979;5:83–102.

27. Bañobre-López M, Teijeiro A, Rivas J. Magnetic nanoparticle-based hyperthermia for cancer treatment. *Rep Pract Oncol Radiother*. 2013;18:397–400.

28. Giustini AJ, Petryk AA, Cassim SM, Tate JA, Baker I, Hoopes PJ. Magnetic nanoparticle hyperthermia in cancer treatment. *Nano Life*. 2010;1, https://doi.org/10.1142/S1793984410000067.

29. Samanta B, Yan H, Fischer NO, Shi J, Jerry DJ, Rotello VM. Protein-passivated Fe3O4 nanoparticles: low toxicity and rapid heating for thermal therapy. *J Mater Chem*. 2008;18:1204–1208.

30. Oh N, Park J. Endocytosis and exocytosis of nanoparticles in mammalian cells. *Int J Nanomedicine*. 2014;9:51–63.

31. Ito A, Kobayashi T. Intracellular hyperthermia using magnetic nanoparticles: a novel method for hyperthermia clinical applications. *Thermal Med*. 2008;24:113–129.

32. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. *J Neurooncol*. 2011;103:317–324.

33. Overgaard J. Ultrastructure of a murine mammary carcinoma exposed to hyperthermia in vivo. *Cancer Res*. 1976;36:983–995.

34. Kocbek P, Králj S, Kreft ME, Kristl J. Targeting intracellular compartments by magnetic polymeric nanoparticles. *Eur J Pharm Sci*. 2013;50:130–138.

35. Niemirowicz K, Prokop I, Wilczewska AZ, et al. Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells. *Int J Nanomedicine*. 2015;10:3843–3853.

36. Gunduz U, Keskin T, Tansik G, et al. Idarubicin-loaded folic acid conjugated magnetic nanoparticles as a targetable drug delivery system for breast cancer. *Biomed Pharmacother*. 2014;68:729–736.

37. Fang L, Chen B, Liu S, et al. Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells. *Int J Nanomedicine*. 2012;7:4109–4118.

38. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. *Science*. 1998;281:1305–1308.

39. Tran SEF, Meinander A, Holmstrom TH, et al. Heat stress downregulates FLIP and sensitizes to Fas-mediated apoptosis. *Cell Death Differ*. 2003;10:1137–1147.

40. Lioussis SN, Ding XZ, Kiang JG, Tsokos GC. Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. *J Immunol*. 1997;158:5668–5675.

41. Mannick JB, Hausladen A, Liu L, et al. Fas-induced caspase deinitrosylation. *Science*. 1999;284:651–654.

42. Ito A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF- gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. *Cancer Gene Ther*. 2001;8:649–654.